pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Sionna Therapeutics, Inc. ($SION) · news · pharmadog
← back to Sionna Therapeutics, Inc.
News mentioning $SION
109
stories
Aug 19, 26
Trump to pick Heidi Overton to lead the FDA
endpoints
Aug 18, 26
Epic is under pressure
endpoints
Aug 13, 26
'Incorrect and misleading' data prompted decision to pull Tavneos in Europe
endpoints
Aug 13, 26
Karyopharm has a month left to salvage its cancer expansion plans
endpoints
Aug 10, 26
Sionna cystic fibrosis drug fails key trial, removing threat to Vertex
biopharma dive
Aug 10, 26
Sionna's surprise cystic fibrosis trial failure sinks hopes of challenging Vertex
endpoints
Aug 10, 26
Sionna’s cystic fibrosis failure is a windfall for Vertex’s blockbuster franchise
biospace
Aug 10, 26
STAT+: Sionna’s experimental cystic fibrosis pill falls flat in mid-stage trial
stat
Aug 10, 26
Sionna’s cystic fibrosis flop sends stock down 90%, but a ‘significant positive’ for Vertex
fiercebiotech
Aug 4, 26
The China Debate: Biotech deserves a deeper discussion
endpoints
Aug 4, 26
Vertex’s biggest overhang: a rival 50 times smaller
biopharma dive
Aug 4, 26
Otsuka succeeds with kidney drug; BioNTech downgrades revenue projection
endpoints
Aug 3, 26
Work ethic becomes a flashpoint as China's biotech pace quickens
endpoints
Jul 31, 26
Pharma groups back changes to 340B rebate pilot
endpoints
Jul 31, 26
Ionis' top scientist Frank Bennett to retire; Recursion selects its first AI chief
endpoints
Jul 29, 26
FTC sues Hims for sharing sensitive health information, billing practices
endpoints
Jul 29, 26
Former Recursion CEO Chris Gibson joins Dimension as operating partner
endpoints
Jul 24, 26
Biogen’s Alzheimer’s data spur excitement, confusion about tau-targeting drugs
endpoints
Jul 23, 26
Sartorius reduces revenue by €26M to refund Trump tariffs to customers
endpoints
Jul 23, 26
Repligen’s $1.5B buy for BioLife; BeOne’s $300M US expansion
endpoints
Jul 22, 26
FDA swiftly puts Makary era in the rearview mirror
endpoints
Jul 22, 26
Mentari adds $200M to migraine mission; Royalty's latest ATTR-CM deal
endpoints
Jul 21, 26
FDA plans to name permanent center heads alongside FDA chief
endpoints
Jul 21, 26
Gilead and Merck provide HIV data; Dimension Capital announces $800M fund
endpoints
Jul 17, 26
Dimerix buys a kidney injury drug; Arpeggio appears to be winding down
endpoints
Jul 15, 26
FDA acting chief walks back Makary's practice of policymaking through journals
endpoints
Jul 14, 26
Draig nets $65M to advance depression drug aimed at rebuilding synapses
endpoints
Jul 9, 26
Roche ends work on tominersen after decade of trials, as well as early-stage Huntington’s asset
endpoints
Jul 8, 26
Sanofi offers to end disparaging claims against CSL flu shot in Europe
endpoints
Jul 7, 26
Vera's IgAN approval kicks off competition with Otsuka
endpoints
← prev
page 2 of 4
next →
